The preliminary documents for the Extraordinary General Shareholder Meeting on 5 October 2017 have been made available Read more about The preliminary documents for the Extraordinary General Shareholder Meeting on 5 October 2017 have been made available
Bone Therapeutics reports strong interim results from ALLOB Phase IIA spinal fusion study Read more about Bone Therapeutics reports strong interim results from ALLOB Phase IIA spinal fusion study
Bone Therapeutics announces all patients meet primary endpoint in ALLOB Phase I/IIA delayed-union study interim analysis Read more about Bone Therapeutics announces all patients meet primary endpoint in ALLOB Phase I/IIA delayed-union study interim analysis
Bone Therapeutics and Asahi Kasei sign exclusive license agreement for PREOB in Japan Read more about Bone Therapeutics and Asahi Kasei sign exclusive license agreement for PREOB in Japan
The preliminary documents for the Extraordinary General Shareholder Meeting on 30 October 2017 have been made available Read more about The preliminary documents for the Extraordinary General Shareholder Meeting on 30 October 2017 have been made available
Bone Therapeutics to participate in upcoming key investor and partnering conferences in Q4 2017 Read more about Bone Therapeutics to participate in upcoming key investor and partnering conferences in Q4 2017
Bone Therapeutics Business Update for Third Quarter 2017 Read more about Bone Therapeutics Business Update for Third Quarter 2017
Bone Therapeutics and Cellthera Pharm LLC announce intention to collaborate and Bone Therapeutics provides overview of its pipeline Read more about Bone Therapeutics and Cellthera Pharm LLC announce intention to collaborate and Bone Therapeutics provides overview of its pipeline
Bone Therapeutics Launches Equity Placement Read more about Bone Therapeutics Launches Equity Placement
Bone Therapeutics Provides Update on Equity Placement Read more about Bone Therapeutics Provides Update on Equity Placement
